MyFinsight
Home
Blog
About
Issuance of common shares
pursuant to exercise of...
$3,148K
(1.35%↑ Y/Y)
Net cash provided by
financing activities
$3,148K
(-2.75%↓ Y/Y)
Increase in cash and cash
equivalents
-$4,535K
(-519.13%↓ Y/Y)
Canceled cashflow
$3,148K
Stock-based compensation
expense
$1,625K
(-63.30%↓ Y/Y)
Prepaid expenses and
other assets
-$215K
(-133.59%↓ Y/Y)
Change in fair value of
contingent consideration
$213K
(-61.90%↓ Y/Y)
Non-cash interest
expense
$13K
(-76.36%↓ Y/Y)
Depreciation
$11K
(-96.77%↓ Y/Y)
Disposition of investments
in marketable...
$22,000K
(-75.60%↓ Y/Y)
Net cash used in
operating activities
-$6,018K
(79.35%↑ Y/Y)
Canceled cashflow
$2,077K
Net cash provided by
investing activities
-$1,661K
(-106.16%↓ Y/Y)
Effect of foreign
exchange rate changes on...
-$4K
(-116.00%↓ Y/Y)
Canceled cashflow
$22,000K
Net income (loss)
-$5,143K
(76.63%↑ Y/Y)
Accounts payable and
accrued liabilities
-$1,624K
(46.86%↑ Y/Y)
Increase (decrease) in
accounts and other...
$632K
Net accretion and
amortization of investments...
$321K
(-76.84%↓ Y/Y)
Non-cash royalty revenue
$180K
(-81.52%↓ Y/Y)
Other liabilities
-$113K
(49.78%↑ Y/Y)
Accounts receivable
$82K
(105.92%↑ Y/Y)
Purchase of investments
in marketable...
$23,662K
(-62.57%↓ Y/Y)
Back
Back
Cash Flow
Arbutus Biopharma Corp (ABUS)
Arbutus Biopharma Corp (ABUS)
source: myfinsight.com